Showing 1 - 2 results of 2 for search 'Tabea Kraft', query time: 0.01s Refine Results
  1. 1
    WCN25-843 FELZARTAMAB REDUCES aPLA2R Ab BY SELECTIVELY DEPLETING CD38+ PLASMA CELLS AND PLASMABLASTS, THE MAIN PATHOGENIC CELLULAR DRIVERS OF DISEASE IN PRIMARY MEMBRANOUS NEPHROPATHY (PMN)

    WCN25-843 FELZARTAMAB REDUCES aPLA2R Ab BY SELECTIVELY DEPLETING CD38+ PLASMA CELLS AND PLASMABLASTS, THE MAIN PATHOGENIC CELLULAR DRIVERS OF DISEASE IN PRIMARY MEMBRANOUS NEPHROPA... by Donna Flesher, Rainer Boxhammer, Tabea Kräft, Millie Shah, Lisa Kivman, Stefan Härtle, Jaideep Dudani, Houston Gilbert, Uptal Patel, Brad Rovin

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN)

    WCN25-318 FELZARTAMAB DURABLY REDUCES DISEASE RELEVANT BIOMARKERS THROUGH TARGETING OF CD38+ PLASMA CELLS AND PLASMABLASTS, THE UPSTREAM DRIVERS OF IgA NEPHROPATHY (IgAN) by Lisa Kivman, Tabea Kraft, Julia Rauser, Rainer Boxhammer, Stefan Hartle, Brian Schwartz, Paul Manser, Leslie Chinn, Uptal Patel, Donna Flesher, Krzysztof Kiryluk, Jonathan Barratt

    Published 2025-02-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: